With the first biosimilar version of a monoclonal antibody now under regulatory review in the European Union, which R&D strategies are innovators relying on to counteract competition?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications
Globalization and Health Open Access 18 September 2019
-
Etanercept biosimilars
Rheumatology International Open Access 01 July 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. Can next-generation antibodies offset biosimilar competition?. Nat Rev Drug Discov 11, 426–428 (2012). https://doi.org/10.1038/nrd3749
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3749
This article is cited by
-
Pharmacokinetics, Tolerability, Safety, and Immunogenicity of LY01008 and Bevacizumab (Avastin®) in Healthy Chinese Subjects
European Journal of Drug Metabolism and Pharmacokinetics (2022)
-
A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications
Globalization and Health (2019)
-
Multi-parametric analysis reveals enhanced G2-phase arrest of an optimized anti-HER2 antibody to inhibit breast cancer
Biotechnology Letters (2017)
-
Innovation in biologic new molecular entities: 1986–2014
Nature Reviews Drug Discovery (2015)
-
Etanercept biosimilars
Rheumatology International (2015)
